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Abstract
Objective To investigate the long term effectiveness of integrated
disease management delivered in primary care on quality of life in
patients with chronic obstructive pulmonary disease (COPD) compared
with usual care.
Design 24 month, multicentre, pragmatic cluster randomised controlled
trial
Setting 40 general practices in the western part of the Netherlands
Participants Patients with COPD according to GOLD (Global Initiative
for COPD) criteria. Exclusion criteria were terminal illness, cognitive
impairment, alcohol or drug misuse, and inability to fill in Dutch
questionnaires. Practices were included if they were willing to create a
multidisciplinary COPD team.
Intervention General practitioners, practice nurses, and specialised
physiotherapists in the intervention group received a two day training
course on incorporating integrated disease management in practice,
including early recognition of exacerbations and self management,
smoking cessation, physiotherapeutic reactivation, optimal diagnosis,
and drug adherence. Additionally, the course served as a network
platform and collaborating healthcare providers designed an individual
practice plan to integrate integrated disease management into daily
practice. The control group continued usual care (based on international
guidelines).
Main outcomemeasures The primary outcome was difference in health
status at 12 months, measured by the Clinical COPD Questionnaire
(CCQ); quality of life, Medical Research Council dyspnoea, exacerbation
related outcomes, self management, physical activity, and level of
integrated care (PACIC) were also assessed as secondary outcomes.
Results Of a total of 1086 patients from 40 clusters, 20 practices (554
patients) were randomly assigned to the intervention group and 20
clusters (532 patients) to the usual care group. No difference was seen
between groups in the CCQ at 12 months (mean difference –0.01, 95%
confidence interval –0.10 to 0.08; P=0.8). After 12 months, no differences
were seen in secondary outcomes between groups, except for the PACIC
domain “follow-up/coordination” (indicating improved integration of care)
and proportion of physically active patients. Exacerbation rates as well
as number of days in hospital did not differ between groups. After 24
months, no differences were seen in outcomes, except for the PACIC
follow-up/coordination domain.
Conclusion In this pragmatic study, an integrated disease management
approach delivered in primary care showed no additional benefit
compared with usual care, except improved level of integrated care and
a self reported higher degree of daily activities. The contradictory findings
to earlier positive studies could be explained by differences between
interventions (provider versus patient targeted), selective reporting of
positive trials, or little room for improvement in the already well developed
Dutch healthcare system.
Trial registration Netherlands Trial Register NTR2268.
Correspondence to: A L Kruis a.l.kruis@lumc.nl
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Chronic obstructive pulmonary disease (COPD) is a disabling
respiratory disease affecting millions of people worldwide.1
Although no medical treatment can modify the course of the
disease, multiple interventions are available to improve the
wellbeing of patients and to reduce unnecessary hospital
admissions due to exacerbations. However, these interventions
are underused or suboptimally implemented.2 Irregular
exacerbations, fluctuating symptoms, and various disabilities
require a collaborative interaction between actively involved
patients and a proactivemultidisciplinary team.3 Such interaction
is promoted by integrated disease management programmes
developed in response to the evidently unsuccessful reactive
response to disease progression.2
Recently, we published a Cochrane systematic review showing
clinically relevant effects on disease specific health related
quality of life and exercise capacity of COPD patients following
an integrated disease management programme for at least three
months.4 The review also showed that integrated disease
management reduced respiratory related hospital admissions
and days in hospital. This led to potential savings in healthcare
costs, as shown in a second review.5 Interestingly, the effects
and cost savings increased with severity of COPD. As COPD
is a disease with increasing prevalence, and general practitioners
and family physicians treat most patients, well designed studies
of pragmatic integrated disease management programmes in
primary care are essential. However, in COPD trials, the
participants commonly comprise a small and selected fraction
of the real world population, resulting in leading medical
journals calling for studies in more representative patient
populations.6 7The few studies of integrated diseasemanagement
in primary care recruited patients in secondary care,8-11 consisted
of palliative programmes for severe patients,12 13 had a short
duration of intervention,9-12 14 or did not correct for cluster
analysis.15 The true effect of integrated disease management in
primary care thus remains inconclusive. Therefore, the aim of
this large pragmatic RECODE (randomized clinical trial on
effectiveness of integrated COPDmanagement in primary care)
cluster randomised trial was to assess whether integrated disease
management implemented in primary care is effective in
improving the quality of life of COPD patients.
Methods
This study was performed in accordance with the study
protocol.16
Study design and patients
We did a 24 month, cluster randomised controlled trial in which
general practitioners were randomly assigned to the intervention
(integrated disease management) or usual care. General
practitioners were recruited from the western part of the
Netherlands. Patients in both groups received an information
leaflet stating that the aim of the study was to improve treatment
of COPD in primary care and that general practitioners were
randomised to two groups. All general practitioners and all
participants gave written informed consent. Eligible participants
had a diagnosis of COPD, according to GOLD (Global Initiative
for COPD) guidelines.1 For all included patients, we attempted
to verify the diagnosis by lung function tests. If spirometry data
were not of sufficient quality or not available, patients were
invited to participate for a lung function assessment, according
to the American Thoracic Society/European Respiratory Society
guidelines for spirometry.17 Exclusion criteria were terminal
illness, cognitive impairment, hard drug or alcohol misuse, and
inability to fill in questionnaires. Recruitment of practices started
in September 2010 and was finished in September 2011.
Intervention
The intervention was delivered at the cluster level. General
practitioners, practice nurses, and specialised physiotherapists
in the intervention group received a two day training course on
incorporating integrated disease management in practice.
Optionally, an additional team member (such as a dietitian or
pulmonary specialist) could attend the course if they expressed
interest. Elements of the course included performing/interpreting
spirometry, assessment of disease burden, review of advice from
international guidelines, motivational interviewing to stimulate
a healthier lifestyle, and smoking cessation. Furthermore, the
healthcare providers were trained in adopting self management
action plans, including early recognition and treatment of
exacerbations, encouragement of regular exercise and guideline
based physical reactivation, cooperation with secondary care,
and instructions in nutritional support. The secondary aim of
the course was to provide a network platform for teammembers.
At the end of the second day, each practice team designed a
specific time contingent plan in a group discussion with their
multidisciplinary members. They decided which elements of
integrated care they wanted to start implementing first, who
would be responsible for which part of the interventions, and
which steps to take to integrate integrated disease management
into their daily practice. The practice plan they agreed to
depended not only on the chairperson and the capacity of the
team but also on the COPD care already provided at baseline
and the priorities and feasibility in their practice. They received
advice on the content and feasibility of their plan from the
experts who guided the training. After six and 12 months, the
intervention practices had a refresher course.
During the course, the team learnt the details of a web based
decision support system for audit and feedback with patients’
and professionals’ portals, named Zorgdraad (“care ties”). The
teams received practice tailored benchmark reports at baseline
and at six and 12 months. All practices were free to determine
and follow their individual plans and could choose to implement
the Zorgdraad programme. The intensity of the integrated
disease management programme for individual patients
depended on health status, personal needs, and preferences, as
well as on the capacity of the general practice team. As a result,
patients with severe disease or at high risk were encouraged to
receive multiple interventions, whereas other (for example,
stable) patients had only regular control visits. All patient care
was covered by the basic health insurance package that is
compulsory in the Netherlands, except physiotherapy, which
was additionally reimbursed for all RECODE patients with a
Medical Research Council dyspnoea score above 2.
Healthcare providers in the control group were asked to continue
their usual care, based on Dutch general practice COPD
guidelines, in line with GOLD guidelines.1 The practice nurses
in the usual care group received a course on technical
performance of spirometry only, to divert attention from topics
related to our intervention.
Randomisation and masking
To enhance comparability, a blinded researcher (NHC) stratified
and matched participating clusters according to the following
criteria: percentage of patients in practice from ethnic minorities,
type of practice (single handed, one or more partner practice,
or healthcare centre), practice location (urban/rural), age of
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general practitioner, and sex of general practitioner. Following
this procedure, the same blinded researcher randomisedmatched
clusters in pairs by using a computer generated list in four blocks
of 10. Because of the nature of the intervention, participating
healthcare providers and patients could not be blinded.
Therefore, blinded research nurses assessed outcomes to
minimise detection bias. Patients were instructed not to report
on their type of management to these research nurses.
Outcomes
All outcomes were assessed at the level of the individual
participant and are reported in supplementary table A. The
primary outcome was change in health related quality of life on
the Clinical COPD Questionnaire (CCQ)18 at 12 months.
Secondary outcomes were change in health related quality of
life as measured by the St George’s Respiratory Questionnaire
(SGRQ),19EuroQol-5D (EQ-5D),20 and Short Form 36 (SF-36).21
In addition, we measured MRC dyspnoea,22 Self-Management
Ability Scale-30 (SMAS-30),23 daily physical activities
(International Physical Activity Questionnaire; IPAQ24), level
of care integration according to patients, measured by the Patient
Assessment Chronic Illness Care (PACIC),25 smoking behaviour,
and healthcare usage (including hospital admissions and
moderate/severe exacerbations). Blinded research nurses
administered these questionnaires at baseline and at six and 12
months. Postal questionnaires were sent at nine, 18, and 24
months. We extracted data on moderate exacerbations over the
complete trial period from electronic medical records at 24
months. We defined a moderate exacerbation as a worsening
of daily symptoms that led a patient’s physician to prescribe
systemic corticosteroids, antibiotics, or both, without hospital
admission. A severe exacerbation occurred when worsening
symptoms required a hospital admission.
Statistical analysis
We based sample size estimates on the mean difference in CCQ
score between intervention and control groups at 12 months.
We used methods for standard sample size estimates for trials
that randomise at the level of the individual,26 adjusting for
clustering by inflating sample size estimates by the design effect
given by 1+(n–1)ρ, where n is the average cluster size and ρ is
the estimated intra-class correlation coefficient.27 Using the
minimal clinically important mean difference of 0.4 for the
CCQ,28 with a standard deviation of CCQ equal to 0.49 at 12
months, and the upper value of 0.05 from a range of intra-class
correlation coefficient values identified in primary care studies,29
power calculations indicated that we needed 40 clusters of
practices with an average of 27 participants per cluster. To allow
for subgroup analysis of MRC scores 1-2 versus 3-5, a total of
1080 participants were needed to achieve a power of at least
80%with α levels of 0.05, including a loss to follow-up of 10%
of participants or a loss of four clusters at 12 months.
The primary effectiveness analysis was an intention to treat
analysis of the difference in mean CCQ score between groups
at 12months. Because of repeatedmeasurements for all patients,
we used linear mixedmodel analyses to assess differences within
and between groups for all continuous outcomes, correcting for
baseline scores, age, sex, proportion of patients withMRC score
above 2, and clustering of patients per general practice.We used
baseline scores as a dependent variable, the cluster was
represented by a random effect, and the within patient covariance
structure was unstructured. For dichotomous outcomes, we used
logistic link generalised linear mixed models for repeated
measurements to analyse differences within and between groups
at all time points, correcting for the same covariates. We
compared differences in two year moderate and severe
exacerbation counts by using the negative binomial model,30
correcting for age, sex, MRC score above 2, exacerbation rate
in the year before baseline, and clustering of patients per
practice. This model returns incidence rate ratios, which in this
case are exacerbation rates. On the basis of the literature, we
did a priori defined subgroup analyses on the primary outcome
of CCQ at 12 months.16
Results
Patients
Figure 1⇓ shows the screening, randomisation, and follow-up
of patients.31 Supplementary figure A shows the dropout rates
at the various time points. Table 1⇓ summarises the baseline
characteristics of the patients. Supplementary table B shows the
characteristics of the general practices. Dropout rates at 12
months (9% intervention v 11% usual care) and 24months (24%
v 26%) were similar in the two groups. Patients who dropped
out at 24 months were significantly older (P=0.002) and had
worse scores on the CCQ, EQ-5D, PACIC, SF-36, SGRQ, and
MRC questionnaires at baseline. Thirty two patients died in the
intervention group and 28 in the usual care group. Causes of
death were comparable between groups (P=0.54): COPD related
(28% intervention; 36% usual care), cardiovascular disease
(16%; 14%), and malignancies (16%; 21%). In 40% of the
intervention patients and in 29% of the usual care patients, the
cause of death was unknown.
Primary outcome
We found no statistically significant difference between the
intervention and usual care groups in the CCQ score at 12
months (mean difference –0.01, 95% confidence interval –0.10
to 0.08; P=0.8) (table 2⇓; fig 2⇓).
Secondary outcomes and subgroup analyses
At 6, 9, 18, and 24 months, we found no statistically significant
difference between intervention and usual care in the CCQ score
(fig 2⇓). At 12 months, the change from baseline in SGRQ,
EQ-5D, SF-36, MRC, and SMAS scores was not significantly
different between the intervention and usual care groups (table
2⇓). The proportion of patients with moderate or high activity
levels at 12 months as measured with the IPAQ improved
significantly in the intervention group compared with the usual
care group (mean difference 10.1; P<0.001). The PACIC domain
“follow-up and coordination,” measuring improvement in
follow-up structure of COPD patients, was significantly higher
in the intervention group at 12 months (mean difference 0.15;
P=0.01). The proportion of current smokers, as well as moderate
and severe exacerbation rates and hospital admission rates, did
not differ (table 2⇓).
After 24 months of follow-up, the PACIC follow-up and
coordination domain remained significantly higher in the
intervention group (data not shown; mean difference 0.15;
P=0.03). The other secondary outcomes did not differ
significantly between groups at 24 months. Subgroup analyses
showed no statistically significant effect of the intervention in
any of the a priori defined subgroups (table 3⇓). We did
additional, a posteriori defined, subgroup analyses, which
showed no significant effect of the intervention (supplementary
table C).
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This cluster randomised trial examined a pragmatic set of
interventions aiming to establish an integrated disease
management programme, delivered by a multidisciplinary team
to primary care patients with COPD. We found no differences
between groups in quality of life, exacerbation related outcomes,
self management, or MRC dyspnoea scores. However,
significantly more patients in the intervention group had a self
reported higher degree of daily activities, and the level of
follow-up and coordination of the COPD patients improved.
Interpretation of findings
The results from our study were contrary to our expectations
and to the positive results of the Cochrane systematic review.4
Several reasons might explain the difference in findings.
Firstly, our intervention was implemented at the level of the
healthcare provider, whereas earlier studies were of patient
targeted interventions. We specifically chose to study a
pragmatic intervention that was developed on the basis of
positive results of a controlled primary care study and
implementation project.32 33 In these times of heavy workload
in primary care, we gave the integrated disease management
teams responsibility to develop their individual practice plans
tailored to their own needs, to ensure ongoing implementation
after the study was finished. This is clearly in contrast to other
integrated disease management studies that applied patient
targeted interventions and operated under more intensively
supported, time consuming, and strictly regulated conditions.4
Therefore, a suboptimal intensity, but more realistic,
implementation of the intervention may have contributed to the
difference in effect between this study and earlier studies.
Secondly, in the intervening years, COPD care in the
Netherlands has substantially evolved, which was partially
unforeseen. Probably one of the most important triggers for
general practitioners to start implementing integrated disease
management was the start of a bundled payment system in 2010,
which was our first study year. Although nationwide
implementation of integrated disease management of COPD is
still lacking, several regional projects have been started during
recent years.34 35 Nowadays, COPD care has a better prepared
delivery systemwith structured collaboration between healthcare
professionals, more and better equipped nurses, and the
development of clinical information systems to support the
professional and the patient.36 Therefore, the considerable drive
by health policies and providers to improve COPD care could
have stimulated general practitioners in the usual care group to
start implementing integrated disease management as well. The
absence of effect due to already high levels of care was pointed
out in other well designed Dutch and English primary care trials,
studying components of COPD care.36-38 In contrast, a
community based integrated intervention for early prevention
and management of COPD in a Chinese setting, with a
potentially larger room for improvement, showed a significant
effect on smoking cessation rates and improvements in
knowledge.39
Thirdly, studies with positive results are more likely to be
published, and in high impact journals. In contrast to trial
settings, healthcare providers trying to implement COPD
programmes in daily life often experience problems with poor
adherence or non-response, owing to lack of time, motivation,
or cooperation of patients. This mismatch was illustrated by
Bjoernshave et al, who showed that the populations included
in the Cochrane systematic review of pulmonary rehabilitation
were highly motivated and not representative of the target
population, as 75% of the initially suitable patients were omitted
owing to exclusion or drop out.40 Additionally, positive trial
results have a higher chance of being referred to in guidelines.
For example, the recent American Thoracic Society/European
Respiratory Society statement41 recommends offering pulmonary
rehabilitation to patients with milder COPD on the basis of
results of two positive trials,8 42whereas negative trials were not
taken into consideration when these recommendations were
formulated.14 43
Strengths and weaknesses of study
To best of our knowledge, this is the largest trial to date
assessing the effectiveness of integrated disease management
in primary care. Important features of this study are the long
term follow-up and the inclusion of a sizeable real world,
heterogeneous study population,6 7 which provided sufficient
power to study differences in effect in subgroup analyses.
Additionally, this pragmatic study included a wide range of
outcomes relevant to primary care, including objective outcomes
(moderate and severe exacerbation rates) and subjective
measures (quality of life).7We applied sophisticated regression
techniques to facilitate the analysis of clustered longitudinal
data.
After 24 months, dropout rates were low but selectively higher
in patients with worse baseline scores. This raises questions of
generalisability, although after correction for baseline scores
no evidence existed for health benefits of the intervention at all,
indicating that dropout is unlikely to have biased the result.
Blinding of participants and clinicians for this type of
intervention was impossible. In an attempt to minimise bias,
blinded research nurses collected the data and patients were
instructed not to talk about their type of intervention. Although
pairing and randomisation of the practices was done by a
member of the research team, he was provided only with the
characteristics of the practices (age and sex of general
practitioner, type of practice). He was blinded to the identity of
the practices and had no contact with the general practitioners.
The included practices were diverse in terms of setting, practice
size, distribution of ethnic minorities, and level of COPD care
at baseline.16 We corrected for most practice related factors by
matching and stratification. However, a pre-existing high level
of COPD care at baseline may have limited the potential for
further improvement in already well developed practices.
Additionally, because of the complex character of the
intervention and the pragmatic study design, we were unable to
assess the effect of individual components of the intervention.
Implications for practice
We found that an integrated disease management programme
implemented in primary care did not improve quality of life and
exacerbation related outcomes in a representative group of Dutch
primary care patients with COPD. We observed an improved
level of follow-up and structure of COPD care, as measured
with the Patient Assessment Chronic Illness Care in the
intervention group over the two year period, indicating important
changes at an organisational level. However, this did not
translate into differences in health outcomes.When interpreting
the unforeseen findings of our study, policy makers and
healthcare professionals should take into account the fact that
primary care for COPD in the Netherlands is already at a high
standard and has further evolved during the years of our
intervention. Effect sizes might be greater in countries where
primary care is less well developed.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g5392 doi: 10.1136/bmj.g5392 (Published 10 September 2014) Page 4 of 11
RESEARCH













J: first published as 10.1136/bm






On the basis of our experiences, an intervention directed at
healthcare providers cannot be recommended for the generality
of COPD patients.We advise application of more intensive, but
still pragmatic programmes aiming at a selection of patients
with a higher burden of disease and thus larger room for
improvement. Exercise can be recognised as a compulsory
element of integrated diseasemanagement.4However, healthcare
providers and insurers should realise that patients with mild
disease often lack the motivation or do not feel the need (yet)
to commit to an intensive (and expensive) integrated care or
exercise programme.14 Therefore, resources are probably better
spent if patients with a higher burden of disease are firstly
thoroughly assessed and stratified for risk, after which a
personalised treatment plan is made using a shared decision
making process between patient and physician. The individual
patient’s needs, preferences, and personal goals should play a
key role in this process. Finally, we should take into account
the fact that COPD is only one of the several chronic conditions
we manage in primary care. Therefore, a more fruitful approach
might be to consider integrated care for a suite of long term
conditions with a high burden of disease, of which COPD is
one component. The absolute number of patients eligible for
this selective approach is probably relatively low, which makes
having proper case management interventions in place possible.
Conclusion
In this study, integrated disease management incorporated in
primary care was not effective in improving quality of life. The
contradictory findings to earlier positive studies could be
explained by differences between interventions (provider- versus
patient targeted), selective reporting of positive trials, or little
room for improvement in the well developed Dutch healthcare
system.
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Table 1| Baseline characteristics of chronic obstructive pulmonary disease patients included in RECODE study. Values are numbers
(percentages) unless stated otherwise




55468.2 (11.3)Mean (SD) age (years)
532305 (57.3)*554280 (50.5)Male sex
493142 28.8505140 27.7Employment
491195 (41.5)498195 (39.2)Low education





40911 (2.7)45814 (3.1)IV—very severe
506196 (38.7)515179 (34.8)Current smoker
Relevant comorbidities:














5292.0 (1.3)5532.0 (1.3)Mean (SD) MRC total score
529167 (31.6)553194 (35.1)MRC score >2
5280.73 (0.28)5460.74 (0.25)Mean (SD) EQ-5D score
53267.3 (17.3)55466.6 (17.6)Mean (SD) EQ-5D VAS score
50338.6 (10.7)51238 (10.9)Mean (SD) SF-36 score, physical component
50348.9 (10.3)51248.3 (10.5)Mean (SD) SF-36 score, mental component
Mean (SD) SMAS score:
50956.9 (17.4)51856.8 (17.8)Taking initiatives
51159.3 (17.9)51761.4 (16.8)Investment behaviour
51264.3 (17.6)51665.7 (17.2)Self-efficacy
5263087 (4809)5463150 (4696)Mean (SD) IPAQ, total MET minutes
52370 (13.4)54154 (10.0)IPAQ, high/moderate
523453 (86.6)541487 (90.0)IPAQ, low
Mean (SD) PACIC score:
4372.3 (0.9)4362.3 (0.9)Total
4352.2 (1.2)4352.4 (1.2)Activation
4362.9 (1.1)4323 (1.2)Delivery system design
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Usual care (n=532; 20 clusters)Intervention (n=554; 20 clusters)
Characteristic ObservationsValueObservationsValue
4332.1 (0.9)4312.2 (1.0)Goal setting
4332.2 (1.0)4302.3 (1.2)Problem solving
4311.8 (0.8)4331.8 (0.9)Follow-up/coordination
Mean (SD) exacerbations:
5320.3 (0.8)5540.4 (0.8)Moderate exacerbation rate (12 months)
5320.02 (0.2)5540.02 (0.2)Severe exacerbation rate (3 months)
5328.6 (4.7)5546 (2.1)Hospital admission days (3 months)
CCQ=Clinical COPD Questionnaire; GOLD=Global Initiative for Chronic Obstructive Pulmonary Disease; EQ-5D=Euro Qol-5D; FEV1=forced expiratory volume in
1 second; IPAQ=International Physical Activity Questionnaire; MET=metabolic equivalent of task; MRC=Medical Research Council; PACIC=Patient Assessment
Chronic Illness Care; SF-36=Short Form 36; SGRQ=St George’s Respiratory Questionnaire; SMAS=Self-Management Ability Scale.
*Statistically significant difference between intervention and usual care groups.
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Table 2| Clinical outcomes: within and between group differences at 12 months, corrected for age, sex, baseline score, and MRC score >2.
Values are mean (95% CI) unless stated otherwise
P valueMean difference (95% CI)Usual care (n=532; 20 clusters)Intervention (n=554; 20 clusters)Outcome
0.80–0.01 (–0.10 to 0.08)0.03 (–0.03 to 0.09)–0.03 (–0.09 to 0.03)CCQ total score
0.590.03 (–0.09 to 0.15)–0.10 (–0.19 to 0.01)–0.07 (–0.15 to 0.02)CCQ—symptoms domain
0.48–0.04 (–0.16 to 0.07)0.21 (0.12 to 0.29)0.16 (0.08 to 0.25)CCQ—functional domain
0.57–0.03 (–0.13 to 0.07)–0.06 (–0.14 to 0.01)–0.09 (–0.16 to –0.02)CCQ—mental domain
0.34–0.73 (–2.25 to 0.78)0.33 (–0.78 to 1.43)–0.40 (–1.46 to 0.65)SGRQ total score
0.42–0.97 ( –3.33 to 1.39)0.22 (–1.52 to 1.96)–0.75 (–2.43 to 0.93)SGRQ—symptoms domain
0.26–1.25 ( –3.41 to 0.90)1.25 ( –0.32 to 2.82)0 ( –1.51 to 1.50)SGRQ—activities domain
0.960.04 ( –1.61 to 1.70)–0.35 (1.96 to 5.33)–0.31 (–1.46 to 0.85)SGRQ—impact domain
0.520.04 (–0.09 to 0.18)0.19 (0.09 to 0.29)0.23 (0.14 to 0.33)MRC dyspnoea score
0.07–0.03 (–0.06 to 0)–0.01 (–0.03 to 0.01)–0.04 (–0.06 to –0.02)EQ-5D
0.800.21 (–1.44 to 1.87)–1.92 (–3.21 to –0.63)–1.71 (–2.95 to 0.46)EQ-5D VAS score
0.23–0.61 (–1.61 to 0.39)–0.48 (–1.23 to 0.26)–1.1 (–1.82 to –0.38)SF-36—physical domain
0.250.64 (–0.45 to 1.73)0.09 (–0.74 to 0.92)0.73 (–0.07 to 1.54)SF-36—mental domain
0.75–0.28 (–2.00 to 1.43)–1 (–2.3 to 0.33)–1.27 (–2.5 to 0)SMAS—taking initiatives
0.93–0.07 (–1.78 to 1.63)–1.43 (–2.73 to –0.12)–1.5 (–2.75 to –0.25)SMAS—investment behaviour
0.35–0.79 (–2.47 to 0.88)–0.38 (–1.65 to 0.89)–1.17 (–2.39 to 0.05)SMAS—self-efficacy
0.18393 (–179 to 965)–438 (–886 to 11)–44 (–475 to 387)IPAQ—total MET minutes
<0.00110.122.132.2IPAQ—high/moderate (%)
0.310.06 (–0.06 to 0.19)–0.08 (–0.18 to 0.02)–0.02 ( –0.11 to 0.08)PACIC—total score
0.760.03 (–0.14 to 0.19)–0.5 (–0.19 to 0.08)–0.03 (–0.16 to 0.1)PACIC—activation
0.430.07 (–0.10 to 0.23)–0.27 (–0.40 to –1.30)–0.20 (–0.32 to –0.8)PACIC—delivery system design
0.100.11 (–0.10 to 0.25)–0.08 (–0.18 to 0.03)0.04 (–0.06 to 0.13)PACIC—goal setting
0.580.04 (–0.10 to 0.19)–0.02 (–0.14 to 0.1)0.02 (–0.09 to 0.14)PACIC—problem solving
0.010.15 (0.04 to 0.26)–0.02 (–0.11 to 0.07)0.13 (0.04 to 0.21)PACIC—follow-up/coordination
0.563.151.748.6Current smokers (%)
0.920.2 (–4.3 to 4.3)10.7 (7.4 to 14.0)10.5 (7.6 to 13.3)Hospital admission days
0.091.22 (0.97 to 1.54)*0.48 (0.37 to 0.62)0.58 (0.45 to 0.75)Moderate exacerbations (rate)
0.421.20 (0.78 to 1.84)*0.10 (0.06 to 0.18)0.13 (0.08 to 0.21)Severe exacerbations (rate)
CCQ=Clinical COPD Questionnaire; EQ-5D=Euro Qol-5D; IPAQ=International Physical Activity Questionnaire; MET=metabolic equivalent of task; MRC=Medical
Research Council; PACIC=Patient Assessment Chronic Illness Care; SF-36=Short Form 36; SGRQ=St George’s Respiratory Questionnaire; SMAS=Self-Management
Ability Scale.
Values are corrected for clustering, age, sex, score at baseline, and MRC score >2.
*Means rate ratio.
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Table 3| Subgroup analyses: difference between intervention and usual care groups in change from baseline to 12 months’ follow-up in
CCQ score for pre-specified subgroups. Values are mean (SE) unless stated otherwise
Subgroup by treatment
interaction P valueP value
Intervention–usual
care
Usual care (20 clusters)Intervention (20 clusters)
Group Mean (SE)NoMean (SE)No
0.82–0.01 (0.04)0.03 (0.03)5320.02 (0.03)554Full cohort
0.3Sex:
0.990 (0.05)0 (0.06)3050 (0.06)280Male
0.66–0.02 (0.05)0.03 (0.03)2270.01 (0.04)274Female
0.15Age:
0.710.02 (0.05)0.15 (0.09)1990.17 (0.09)212<65 years
0.54–0.03 (0.05)0.03 (0.03)3330 (0.04)342≥65 years
0.47GOLD stage:
0.460.04 (0.05)–0.33 (0.07)317–0.29 (0.07)357I-II
0.960 (0.07)0.03 (0.04)920.03 (0.06)101III-IV
0.2MRC score:
0.970 (0.05)0.03 (0.03)3620.03 (0.04)359≤2
0.63–0.03 (0.06)1.13 (0.06)1671.10 (0.07)194>2
Lower CCQ score means better quality of life. Values are corrected for clustering, age, sex, score at baseline, and MRC score >2.
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Fig 1 Flow diagram of RECODE study
Fig 2 Change in Clinical COPD Questionnaire (CCQ) score at 6, 9, 12, 18, and 24 months, corrected for age, sex, baseline
CCQ score, and MRC score above 2. Error bars represent standard errors. Score lower than 0 means improvement
compared with baseline
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